Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: MASH - Metabolic Dysfunction-Associated Steatohepatitis

In brief

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.

Key facts

Study ID

NCT07335601

Run by

Madrigal Pharmaceuticals, Inc.

People needed

120

Starts

2025-12-29

Expected to finish

2029-03-01

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 12 months post-liver transplant at screening and meeting one of the following:
• Cohort 1: Liver transplant for MASH cirrhosis with recurrent hepatic steatosis ≥8% by MRI-PDFF
• Cohort 2: Liver transplant for non-MASH etiology with de novo hepatic steatosis ≥8% by MRI-PDFF
• Presence of at least one metabolic risk factor, including overweight/obesity, dysglycemia or type 2 diabetes, hypertension or antihypertensive treatment, hypertriglyceridemia or low HDL cholesterol, or lipid-lowering therapy.
• MASH with moderate to advanced liver fibrosis (F2-F3), confirmed by noninvasive fibrosis assessment (FibroScan and/or MRE) and a liver biopsy consistent with Stage F2/F3 MASH and no evidence of other liver pathology or graft rejection.
• Stable renal function with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² prior to and during screening.
• Stable liver enzymes at screening, without clinically significant worsening compared with recent historical values.
• Stable immunosuppressive regimen for at least 3 months prior to screening.
• Females of childbearing potential must have a negative pregnancy test, not be breastfeeding, and agree to use effective contraception during the study and for at least 30 days after the last dose; females not of childbearing potential are eligible.

You may not qualify if…

• Participation in another interventional clinical trial with investigational drug exposure within 30 days (or 5 half-lives, whichever is longer) prior to screening.
• Phosphatidylethanol (PEth) value of ≥20 ng/mL measured at screening or clinically significant alcohol use within 1 year prior to screening.
• FibroScan VCTE >20 kPa, a baseline biopsy demonstrating fibrosis consistent with F4, or MRE > 5 kPa.
• Uncontrolled or clinically significant thyroid disease, including active hyperthyroidism or untreated hypothyroidism.
• Evidence of active liver disease other than MASH.
• History of liver transplantation for an inborn error of metabolism.
• Evidence of hepatic impairment or decompensation at screening.
• Steroid resistant rejection of the transplanted liver or kidney, or a history of a rejection treated with high dose steroid within 3 months of screening.
• Chronic rejection or chronic plasma-cell hepatitis.
• Significant post-transplant vascular or biliary complications.
• Significant cardiovascular or cerebrovascular disease within 6 months prior to randomization.
• Uncontrolled hypertension at screening or randomization.
• Current hepatocellular carcinoma.
• Known human immunodeficiency virus (HIV) infection or other clinically significant immunocompromised state.
• Any serious medical condition with a life expectancy of less than 5 years.
• Current substance abuse or drug addiction.
• Significant psychiatric, cognitive, or social conditions that would interfere with study participation or compliance, in the Investigator's judgment.
• Known hypersensitivity to study drug or any of its excipients.
• Use of prohibited concomitant medications that may affect liver function, steatosis, thyroid function, or study outcomes, or unstable doses of allowed metabolic therapies prior to randomization.
• Use of statins above protocol-allowed doses or unstable lipid-lowering therapy prior to randomization.
• Contraindications to MRI, including implanted devices incompatible with MRI, severe claustrophobia, or inability to undergo MRI procedures.

Where it is running

• Vanderbilt University Medical Center (VUMC) — Nashville, Tennessee, United States (enrolling)
• Dallas Methodist — Dallas, Texas, United States (enrolling)
• Houston Methodist Hospital — Houston, Texas, United States (enrolling)
• Intermountain Medical Center — Murray, Utah, United States (enrolling)
• Northwestern University — Chicago, Illinois, United States (enrolling)
• University of California San Diego — La Jolla, California, United States (enrolling)
• University of Colorado — Aurora, Colorado, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• University of California, San Francisco — San Francisco, California, United States (enrolling)
• Northwell Health Inc, Center for Liver Disease and Transplantation — Manhasset, New York, United States (enrolling)
• NY Presbyterian- Weill Cornell Medicine — New York, New York, United States (enrolling)
• University Health Network - Toronto General Hospital (TGH) — Toronto, Ontario, Canada
• University of California Los Angeles Medical Center — Los Angeles, California, United States
• Medstar Georgetown University Hospital — Washington D.C., District of Columbia, United States
• The University of Chicago Medicine — Chicago, Illinois, United States
• University of Nebraska — Omaha, Nebraska, United States
• University of Virginia Health System — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.